Painkillers dull pain without erasing all sensation
That is the conceptual line between analgesics and anesthetics. Greeks gave us the word—without pain—and before the twentieth century English speakers often said anodynes. Today the everyday toolkit runs from supermarket NSAIDs to tightly watched opioids.
An analgesic is any drug used to manage pain. Unlike anesthetics, which temporarily reduce or erase sensation, analgesics target pain itself—though neurophysiology overlaps and some agents do both. Choice also tracks pain type: for neuropathic pain, researchers increasingly look beyond classic painkillers to tricyclic antidepressants and anticonvulsants. Many NSAIDs sit over the counter; stronger agents stay prescription-only because overdose, misuse, and addiction risks soar without supervision.
Mechanisms slice the shelf into families. Paracetamol (acetaminophen) handles mild to moderate pain and fever for two to four hours and pairs with opioids for severe cancer or postsurgical pain; it is generally safe at recommended doses. NSAIDs such as aspirin, ibuprofen, naproxen, and diclofenac cut pain, fever, and, at higher doses, inflammation by blocking cyclooxygenase. COX-2–selective drugs (celecoxib, etoricoxib, the withdrawn rofecoxib) aimed to spare gut bleeding, then most of the class raised average cardiovascular event risk by about 40 percent—prompting withdrawals and warnings. Opioids from morphine to oxycodone engage cerebral opioid receptors; tramadol mixes weak μ-agonism with serotonin–norepinephrine effects. Constipation hits almost everyone on opioids; nausea, itch, and respiratory depression set dose ceilings.
Other paths complicate the story. Alcohol can lessen some pain yet also feed alcohol use disorder. Medical cannabis shows evidence for chronic pain and spasms, with some trials favoring it over opioids for neuropathic pain. Combination pills (paracetamol plus codeine, or NSAIDs with decongestants) sometimes add little efficacy while inviting accidental overdose from confusing ingredients. Alternative-medicine pain claims occasionally beat placebo in limited studies, but reviewers say more rigorous work is needed. Nefopam, a monoamine and ion-channel modulator, is approved for moderate to severe pain in some countries. The shared goal is quieter pain signals—not a numb world.
Source: Analgesic
